Meaningful patient representation informing Canada’s cancer drug funding decisions: views of patient representatives on the Pan-Canadian Oncology Drug Review

  • J.S. Hoch Pharmacoeconomics Research Unit, Cancer Care Ontario
  • M.B. Brown
  • C. McMahon
  • J. Nanson
  • L. Rozmovits
Keywords: Oncology drug funding, pcodr, health economics

Abstract

In this interview with the patient representatives on the Expert Review Committee (perc) of the Pan-Canadian Oncology Drug Review (pcodr), those representatives offer their views about how to be a valuable contributing member of Canada’s national cancer drug funding recommendation committee. The article seeks to inform readers, and especially clinicians, about pcodr from the perspective of the patient representatives.

Author Biography

J.S. Hoch, Pharmacoeconomics Research Unit, Cancer Care Ontario
Jeffrey Hoch received his PhD in health economics from the Johns Hopkins School of Public Health. He also holds a Masters in Economics from Johns Hopkins University, and a Bachelor of Arts degree in Quantitative Economics and Decision Sciences from the University of California at San Diego. An award winning teacher, Dr Hoch has taught Health Economics and Economic Evaluation classes in Canada, the United States and internationally. In 2007, he was asked to develop and direct the Pharmacoeconomics Research Unit at Cancer Care Ontario. As Director of the unit, Dr Hoch has pursued research making health economics more useful to decision makers.  Dr. Hoch is also the co-Director of the Canadian Centre for Applied Research in Cancer Control (ARCC).  ARCC is a national research centre dedicated to cancer research, capacity building and knowledge transfer related to health economics, services, policy and ethics.  Dr. Hoch’s research interests include health services research related to cancer, mental health, and other health issues affecting poor and vulnerable populations.
Published
2014-07-03
How to Cite
Hoch, J., Brown, M., McMahon, C., Nanson, J., & Rozmovits, L. (2014). Meaningful patient representation informing Canada’s cancer drug funding decisions: views of patient representatives on the Pan-Canadian Oncology Drug Review. Current Oncology, 21(5), 263-266. https://doi.org/10.3747/co.21.2128
Section
Patient Representatives’ Views of the pCODR